Albert Koong

Clinical Trials

• Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• Not Recruiting PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
• Not Recruiting Combination SBRT (Stereotactic Body Radiotherapy) With TACE (Transarterial Chemoembolization) for Unresectable Hepatocellular Carcinoma
• Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
• Not Recruiting Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
• Not Recruiting Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
• Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
• Recruiting Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
• Recruiting Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
• Not Recruiting Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
• Not Recruiting Evaluation of Stereotactic Radiosurgery For Liver Malignancies
• Not Recruiting Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
• Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
• Not Recruiting Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
• Not Recruiting The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
• Not Recruiting Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
• Not Recruiting S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
• Not Recruiting Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
• Not Recruiting Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
• Not Recruiting A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
• Not Recruiting QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
• Not Recruiting Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer
• Recruiting Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers